Ultragenyx Pharmaceutical (RARE) News Today $45.40 -0.38 (-0.83%) (As of 12/16/2024 ET) Add Compare Share Share Headlines Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSustainabilityTrends All Sources Trusted Sources MarketBeat Benzinga Bloomberg GuruFocus MarketWatch Motley Fool NASDAQ PR Newswire Reuters Seeking Alpha TalkMarkets The Street TipRanks The Wall Street Journal Wall Street Zen Yahoo Finance Source Sentiment refers to the positivity or negativity of each headline according to our language processing algorithm. Sentiment All Sentiments Very Positive Positive Neutral Negative Very Negative Most Recent December 2024 November 2024 October 2024 September 2024 August 2024 July 2024 June 2024 May 2024 April 2024 March 2024 February 2024 January 2024 December 2023 November 2023 October 2023 September 2023 August 2023 July 2023 June 2023 May 2023 April 2023 March 2023 February 2023 January 2023 December 2022 November 2022 October 2022 September 2022 August 2022 July 2022 June 2022 May 2022 April 2022 March 2022 February 2022 January 2022 Time Period Ultragenyx Pharmaceutical Inc. (NASDAQ:RARE) Receives Consensus Recommendation of "Moderate Buy" from AnalystsShares of Ultragenyx Pharmaceutical Inc. (NASDAQ:RARE - Get Free Report) have earned a consensus rating of "Moderate Buy" from the thirteen research firms that are presently covering the stock, Marketbeat Ratings reports. One analyst has rated the stock with a hold recommendation and twelve have aDecember 15 at 4:38 AM | marketbeat.comState Street Corp Lowers Stock Position in Ultragenyx Pharmaceutical Inc. (NASDAQ:RARE)State Street Corp lowered its position in Ultragenyx Pharmaceutical Inc. (NASDAQ:RARE - Free Report) by 1.2% in the 3rd quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The fund owned 2,664,077 shares of the biopharmaceutical coDecember 14 at 4:09 AM | marketbeat.comY Intercept Hong Kong Ltd Buys 12,617 Shares of Ultragenyx Pharmaceutical Inc. (NASDAQ:RARE)Y Intercept Hong Kong Ltd raised its position in shares of Ultragenyx Pharmaceutical Inc. (NASDAQ:RARE - Free Report) by 193.1% in the 3rd quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The firm owned 19,151 shares of the biopharmacDecember 13, 2024 | marketbeat.comJanus Henderson Group PLC Has $2.03 Million Stock Holdings in Ultragenyx Pharmaceutical Inc. (NASDAQ:RARE)Janus Henderson Group PLC trimmed its position in Ultragenyx Pharmaceutical Inc. (NASDAQ:RARE - Free Report) by 49.1% in the third quarter, according to its most recent filing with the SEC. The fund owned 36,543 shares of the biopharmaceutical company's stock after selling 35,200 shares during theDecember 13, 2024 | marketbeat.comUltragenyx Pharmaceutical Inc. (NASDAQ:RARE) CEO Sells $413,650.00 in StockDecember 12, 2024 | insidertrades.comTD Cowen Keeps Their Buy Rating on Ultragenyx Pharmaceutical (RARE)December 11, 2024 | markets.businessinsider.comFrazier Life Sciences Management L.P. Has $35.20 Million Stake in Ultragenyx Pharmaceutical Inc. (NASDAQ:RARE)Frazier Life Sciences Management L.P. lifted its position in shares of Ultragenyx Pharmaceutical Inc. (NASDAQ:RARE - Free Report) by 49.1% in the 3rd quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The firm owned 633,715 shares of the biopharDecember 10, 2024 | marketbeat.comWellington Management Group LLP Lowers Holdings in Ultragenyx Pharmaceutical Inc. (NASDAQ:RARE)Wellington Management Group LLP trimmed its stake in shares of Ultragenyx Pharmaceutical Inc. (NASDAQ:RARE - Free Report) by 8.6% during the 3rd quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The firm owned 4,165,424 shares of theDecember 9, 2024 | marketbeat.comUltragenyx Pharmaceutical Inc. (NASDAQ:RARE) Holdings Decreased by BNP Paribas Financial MarketsBNP Paribas Financial Markets reduced its stake in shares of Ultragenyx Pharmaceutical Inc. (NASDAQ:RARE - Free Report) by 57.3% during the third quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The institutional investor owned 28,831 sDecember 9, 2024 | marketbeat.comJacobs Levy Equity Management Inc. Has $5.44 Million Stock Holdings in Ultragenyx Pharmaceutical Inc. (NASDAQ:RARE)Jacobs Levy Equity Management Inc. lowered its holdings in shares of Ultragenyx Pharmaceutical Inc. (NASDAQ:RARE - Free Report) by 84.6% in the third quarter, according to its most recent 13F filing with the SEC. The institutional investor owned 97,960 shares of the biopharmaceutical company's stoDecember 7, 2024 | marketbeat.comPoint72 DIFC Ltd Has $806,000 Holdings in Ultragenyx Pharmaceutical Inc. (NASDAQ:RARE)Point72 DIFC Ltd raised its position in shares of Ultragenyx Pharmaceutical Inc. (NASDAQ:RARE - Free Report) by 443.9% during the 3rd quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The firm owned 14,517 shares of the biopharmaceuticalDecember 6, 2024 | marketbeat.comUltragenyx Pharmaceutical Inc. (NASDAQ:RARE) Shares Acquired by Point72 Asset Management L.P.Point72 Asset Management L.P. increased its position in Ultragenyx Pharmaceutical Inc. (NASDAQ:RARE - Free Report) by 35.9% in the third quarter, according to its most recent disclosure with the SEC. The institutional investor owned 653,660 shares of the biopharmaceutical company's stock after purDecember 6, 2024 | marketbeat.comRTW Investments LP Lowers Stake in Ultragenyx Pharmaceutical Inc. (NASDAQ:RARE)RTW Investments LP decreased its position in Ultragenyx Pharmaceutical Inc. (NASDAQ:RARE - Free Report) by 39.6% during the 3rd quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The institutional investor owned 1,968,002 shares of the biDecember 5, 2024 | marketbeat.comCinctive Capital Management LP Decreases Stock Holdings in Ultragenyx Pharmaceutical Inc. (NASDAQ:RARE)Cinctive Capital Management LP lessened its stake in shares of Ultragenyx Pharmaceutical Inc. (NASDAQ:RARE - Free Report) by 87.4% during the third quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The fund owned 15,902 shares of the biopDecember 4, 2024 | marketbeat.comBamco Inc. NY Takes Position in Ultragenyx Pharmaceutical Inc. (NASDAQ:RARE)Bamco Inc. NY purchased a new position in shares of Ultragenyx Pharmaceutical Inc. (NASDAQ:RARE - Free Report) in the third quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The institutional investor purchased 48,000 shares of the biopharmaceDecember 4, 2024 | marketbeat.comErste Asset Management GmbH Purchases Shares of 15,010 Ultragenyx Pharmaceutical Inc. (NASDAQ:RARE)Erste Asset Management GmbH purchased a new stake in shares of Ultragenyx Pharmaceutical Inc. (NASDAQ:RARE - Free Report) in the 3rd quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The firm purchased 15,010 shares of the biopharmaceuticDecember 4, 2024 | marketbeat.comVerition Fund Management LLC Trims Position in Ultragenyx Pharmaceutical Inc. (NASDAQ:RARE)Verition Fund Management LLC lessened its stake in shares of Ultragenyx Pharmaceutical Inc. (NASDAQ:RARE - Free Report) by 43.7% in the third quarter, according to its most recent filing with the Securities & Exchange Commission. The institutional investor owned 77,306 shares of the biopharmacDecember 4, 2024 | marketbeat.comCharles Schwab Investment Management Inc. Acquires 56,905 Shares of Ultragenyx Pharmaceutical Inc. (NASDAQ:RARE)Charles Schwab Investment Management Inc. grew its holdings in shares of Ultragenyx Pharmaceutical Inc. (NASDAQ:RARE - Free Report) by 10.6% during the third quarter, according to the company in its most recent disclosure with the SEC. The fund owned 594,521 shares of the biopharmaceutical company'December 4, 2024 | marketbeat.comCerity Partners LLC Purchases Shares of 31,919 Ultragenyx Pharmaceutical Inc. (NASDAQ:RARE)Cerity Partners LLC acquired a new stake in shares of Ultragenyx Pharmaceutical Inc. (NASDAQ:RARE - Free Report) during the 3rd quarter, according to its most recent 13F filing with the SEC. The firm acquired 31,919 shares of the biopharmaceutical company's stock, valued at approximately $1,773,000December 3, 2024 | marketbeat.comBaker BROS. Advisors LP Boosts Stock Position in Ultragenyx Pharmaceutical Inc. (NASDAQ:RARE)Baker BROS. Advisors LP increased its position in Ultragenyx Pharmaceutical Inc. (NASDAQ:RARE - Free Report) by 7.5% in the 3rd quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The institutional investor owned 1,576,114 shares of the biopharmaceutical cDecember 2, 2024 | marketbeat.comVestal Point Capital LP Sells 1,050,000 Shares of Ultragenyx Pharmaceutical Inc. (NASDAQ:RARE)Vestal Point Capital LP lessened its stake in Ultragenyx Pharmaceutical Inc. (NASDAQ:RARE - Free Report) by 58.3% in the 3rd quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The firm owned 750,000 shares of the biopharmaceutical company's stNovember 29, 2024 | marketbeat.comCapstone Investment Advisors LLC Takes Position in Ultragenyx Pharmaceutical Inc. (NASDAQ:RARE)Capstone Investment Advisors LLC acquired a new position in Ultragenyx Pharmaceutical Inc. (NASDAQ:RARE - Free Report) in the third quarter, according to its most recent Form 13F filing with the SEC. The institutional investor acquired 13,089 shares of the biopharmaceutical company's stock, valuedNovember 29, 2024 | marketbeat.comSuvretta Capital Management LLC Sells 910,112 Shares of Ultragenyx Pharmaceutical Inc. (NASDAQ:RARE)Suvretta Capital Management LLC cut its holdings in Ultragenyx Pharmaceutical Inc. (NASDAQ:RARE - Free Report) by 44.1% in the 3rd quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The institutional investor owned 1,151,314 shares oNovember 29, 2024 | marketbeat.comUltragenyx Pharmaceutical Inc. (NASDAQ:RARE) Shares Bought by Alkeon Capital Management LLCAlkeon Capital Management LLC boosted its holdings in shares of Ultragenyx Pharmaceutical Inc. (NASDAQ:RARE - Free Report) by 34.3% in the 3rd quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission (SEC). The fund owned 3,011,716 shares of the biNovember 29, 2024 | marketbeat.com25,100 Shares in Ultragenyx Pharmaceutical Inc. (NASDAQ:RARE) Acquired by Acuta Capital Partners LLCAcuta Capital Partners LLC purchased a new stake in Ultragenyx Pharmaceutical Inc. (NASDAQ:RARE - Free Report) during the third quarter, according to the company in its most recent filing with the SEC. The firm purchased 25,100 shares of the biopharmaceutical company's stock, valued at approximatelNovember 28, 2024 | marketbeat.comUltragenyx to Participate in Investor Conferences in DecemberNovember 26, 2024 | globenewswire.comAlgert Global LLC Has $4.11 Million Stock Holdings in Ultragenyx Pharmaceutical Inc. (NASDAQ:RARE)Algert Global LLC increased its position in shares of Ultragenyx Pharmaceutical Inc. (NASDAQ:RARE - Free Report) by 46.9% in the third quarter, according to its most recent 13F filing with the Securities & Exchange Commission. The institutional investor owned 73,902 shares of the biopharmaceutNovember 26, 2024 | marketbeat.comMassachusetts Financial Services Co. MA Raises Stock Holdings in Ultragenyx Pharmaceutical Inc. (NASDAQ:RARE)Massachusetts Financial Services Co. MA lifted its holdings in Ultragenyx Pharmaceutical Inc. (NASDAQ:RARE - Free Report) by 46.5% during the 3rd quarter, according to the company in its most recent Form 13F filing with the SEC. The firm owned 542,373 shares of the biopharmaceutical company's stockNovember 26, 2024 | marketbeat.comSwiss National Bank Grows Stock Holdings in Ultragenyx Pharmaceutical Inc. (NASDAQ:RARE)Swiss National Bank raised its stake in Ultragenyx Pharmaceutical Inc. (NASDAQ:RARE - Free Report) by 9.1% in the third quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The institutional investor owned 159,152 shares of the biopharmaceutiNovember 26, 2024 | marketbeat.comUltragenyx Pharmaceutical Inc. (NASDAQ:RARE) Shares Acquired by Natixis Advisors LLCNatixis Advisors LLC lifted its holdings in Ultragenyx Pharmaceutical Inc. (NASDAQ:RARE - Free Report) by 290.0% in the third quarter, according to its most recent disclosure with the SEC. The institutional investor owned 52,562 shares of the biopharmaceutical company's stock after purchasing an aNovember 25, 2024 | marketbeat.comUltragenyx Pharmaceutical Inc. (NASDAQ:RARE) Shares Sold by Connor Clark & Lunn Investment Management Ltd.Connor Clark & Lunn Investment Management Ltd. lowered its stake in Ultragenyx Pharmaceutical Inc. (NASDAQ:RARE - Free Report) by 53.8% in the 3rd quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The firm owned 75,265 shares of the biopharmaceuticNovember 24, 2024 | marketbeat.comB. Metzler seel. Sohn & Co. Holding AG Acquires New Position in Ultragenyx Pharmaceutical Inc. (NASDAQ:RARE)B. Metzler seel. Sohn & Co. Holding AG bought a new position in shares of Ultragenyx Pharmaceutical Inc. (NASDAQ:RARE - Free Report) during the third quarter, according to the company in its most recent disclosure with the SEC. The firm bought 23,817 shares of the biopharmaceutical company's stock,November 23, 2024 | marketbeat.comBNP PARIBAS ASSET MANAGEMENT Holding S.A. Decreases Stock Holdings in Ultragenyx Pharmaceutical Inc. (NASDAQ:RARE)BNP PARIBAS ASSET MANAGEMENT Holding S.A. reduced its position in shares of Ultragenyx Pharmaceutical Inc. (NASDAQ:RARE - Free Report) by 12.8% in the third quarter, according to its most recent filing with the Securities & Exchange Commission. The fund owned 724,182 shares of the biopharmaceutNovember 22, 2024 | marketbeat.comPrincipal Financial Group Inc. Grows Stock Holdings in Ultragenyx Pharmaceutical Inc. (NASDAQ:RARE)Principal Financial Group Inc. boosted its stake in Ultragenyx Pharmaceutical Inc. (NASDAQ:RARE - Free Report) by 740.0% during the 3rd quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The institutional investor owned 86,440 shares of the bNovember 22, 2024 | marketbeat.comUltragenyx Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)November 20, 2024 | globenewswire.comUltragenyx Pharmaceutical Inc. (NASDAQ:RARE) Given Consensus Recommendation of "Moderate Buy" by AnalystsShares of Ultragenyx Pharmaceutical Inc. (NASDAQ:RARE - Get Free Report) have been assigned a consensus recommendation of "Moderate Buy" from the thirteen ratings firms that are covering the company, MarketBeat Ratings reports. One analyst has rated the stock with a hold rating and twelve have issNovember 20, 2024 | marketbeat.comState of New Jersey Common Pension Fund D Reduces Position in Ultragenyx Pharmaceutical Inc. (NASDAQ:RARE)State of New Jersey Common Pension Fund D lessened its holdings in shares of Ultragenyx Pharmaceutical Inc. (NASDAQ:RARE - Free Report) by 28.7% during the 3rd quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The fund owned 34,769 shares of the biopharNovember 18, 2024 | marketbeat.comStrong Buy Rating for Ultragenyx Pharmaceutical: Promising Phase 3 Prospects and Market ConfidenceNovember 13, 2024 | markets.businessinsider.comUltragenyx: Ready For More Growth After Q3 Earnings BeatNovember 12, 2024 | seekingalpha.comUltragenyx Pharmaceutical's (RARE) "Buy" Rating Reaffirmed at Canaccord Genuity GroupCanaccord Genuity Group reissued a "buy" rating and issued a $121.00 target price on shares of Ultragenyx Pharmaceutical in a report on Tuesday.November 12, 2024 | marketbeat.comFY2024 EPS Estimates for RARE Raised by Cantor FitzgeraldUltragenyx Pharmaceutical Inc. (NASDAQ:RARE - Free Report) - Equities research analysts at Cantor Fitzgerald lifted their FY2024 earnings per share estimates for Ultragenyx Pharmaceutical in a research note issued to investors on Wednesday, November 6th. Cantor Fitzgerald analyst K. Kluska now foNovember 11, 2024 | marketbeat.comUltragenyx Presents Positive Update on GTX-102 Angelman Syndrome Program at FAST’s 17th Annual Global Science SummitNovember 9, 2024 | uk.finance.yahoo.comUltragenyx posts trial data backing Phase 3 design for Angelman syndrome therapyNovember 9, 2024 | msn.comUltragenyx Presents Positive Update on GTX-102 Angelman Syndrome Program at FAST's 17th Annual Global Science SummitNovember 9, 2024 | globenewswire.comWhat is HC Wainwright's Estimate for RARE FY2024 Earnings?Ultragenyx Pharmaceutical Inc. (NASDAQ:RARE - Free Report) - Research analysts at HC Wainwright lifted their FY2024 earnings per share (EPS) estimates for Ultragenyx Pharmaceutical in a research note issued on Wednesday, November 6th. HC Wainwright analyst E. Arce now expects that the biopharmaceNovember 8, 2024 | marketbeat.comLeerink Partnrs Has Pessimistic View of RARE FY2024 EarningsUltragenyx Pharmaceutical Inc. (NASDAQ:RARE - Free Report) - Equities research analysts at Leerink Partnrs decreased their FY2024 earnings estimates for Ultragenyx Pharmaceutical in a research note issued on Tuesday, November 5th. Leerink Partnrs analyst J. Schwartz now forecasts that the biopharNovember 8, 2024 | marketbeat.comWhat is Wedbush's Forecast for RARE FY2024 Earnings?Ultragenyx Pharmaceutical Inc. (NASDAQ:RARE - Free Report) - Investment analysts at Wedbush dropped their FY2024 earnings per share estimates for Ultragenyx Pharmaceutical in a report released on Wednesday, November 6th. Wedbush analyst L. Chico now expects that the biopharmaceutical company willNovember 8, 2024 | marketbeat.comEquities Analysts Set Expectations for RARE Q1 EarningsUltragenyx Pharmaceutical Inc. (NASDAQ:RARE - Free Report) - Equities researchers at HC Wainwright issued their Q1 2025 earnings per share (EPS) estimates for Ultragenyx Pharmaceutical in a research note issued to investors on Wednesday, November 6th. HC Wainwright analyst E. Arce forecasts thatNovember 7, 2024 | marketbeat.comEvercore ISI Sticks to Its Buy Rating for Ultragenyx Pharmaceutical (RARE)November 7, 2024 | markets.businessinsider.comBank of America Securities Sticks to Their Buy Rating for Ultragenyx Pharmaceutical (RARE)November 6, 2024 | markets.businessinsider.com Get Ultragenyx Pharmaceutical News Delivered to You Automatically Sign up to receive the latest news and ratings for RARE and its competitors with MarketBeat's FREE daily newsletter. Email Address Bill Gates’ is about to mint millionaires (again) with Stargate. (Ad)This little-known project that Bill Gates has been quietly working on that’s about to unleash an AI breakthrough so advanced, it’s going to make ChatGPT look like VHS. But what’s even more unbelievable? I believe it’ll make Nvidia’s meteoric rise look like a backyard bottle rocket. Click here and I’ll tell you everything you need to know. RARE Media Mentions By Week RARE Media Sentiment Learn about the media sentiment score. Each headline receives a score ranging from 2 (good news) to -2 (bad news). Our company news sentiment scores track the average news sentiment of articles about each company over the most recent 7 days in order to identify companies that are receiving positive press. RARE News Sentiment▼1.040.80▲Average Medical News Sentiment RARE News Coverage Learn about the media coverage comparison. We track news headlines from hundreds of news outlets and tag them by company. This chart compares the number of articles about this company in the last seven days compared with the average number of articles about this company on a typical week. RARE Articles This Week▼96▲RARE Articles Average Week Get Ultragenyx Pharmaceutical News Delivered to You Automatically Sign up to receive the latest news and ratings for RARE and its competitors with MarketBeat's FREE daily newsletter. Email Address Related Companies and Tools Related Companies Moderna News Viatris News Summit Therapeutics News Genmab A/S News Dr. Reddy's Laboratories News Sarepta Therapeutics News Catalent News Vaxcyte News Qiagen News Intra-Cellular Therapies News Headlines Tools Trending Media MentionsHigh Media Sentiment StocksLive News FeedMarketBeat OriginalsStock Ideas This page (NASDAQ:RARE) was last updated on 12/17/2024 by MarketBeat.com Staff From Our PartnersAI breakthrough about to upend industryEveryone is talking about AI right now. The talk has been endless ever since ChatGPT was released to the m...Porter & Company | SponsoredDid You See Trump’s Bombshell Exec. Order 001?Biden broke it... Now Trump is going to fix it. Starting with "Exec. Order 001."Banyan Hill Publishing | Sponsored$2 Trillion Disappears Because of Fed's Secretive New Move$2 trillion has disappeared from the US government's books. The reason why is a new, secretive move being c...Stansberry Research | SponsoredMusk’s new company could top a trillion?The investment legend who predicted the rise of Bitcoin, Facebook and streaming services like Netflix… Just...Paradigm Press | SponsoredElon Musk’s chilling warning for humanityThe 'invasion' I've discovered has nothing to do with the border crisis. What's happening at our southern bord...The Freeport Society | SponsoredThe #1 Crypto for AIWe’ve issued an urgent landmark trade alert for a new crypto wonder. So, I decided to give you this heads-u...Weiss Ratings | Sponsored⭕ [URGENT] Buy Alert just triggeredMy absolute favorite stock just hit a critical "buy now" trigger price.Behind the Markets | SponsoredURGENT: This Altcoin Opportunity Won’t Wait – Act NowCrypto has officially entered the "banana zone" – that wild phase where prices can 1000x in days. It happen...Crypto Swap Profits | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Ultragenyx Pharmaceutical Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Ultragenyx Pharmaceutical With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
